|Bid||18.68 x 1400|
|Ask||19.35 x 2200|
|Day's Range||18.89 - 19.68|
|52 Week Range||11.59 - 22.22|
|Beta (5Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech stocks require only a few select indicators to send a share price soaring, or conversely, to cause it to tumble mercilessly down the charts. An FDA decision or results from a clinical trial have the ability to impact the stock’s direction either way, often dramatically so.On the Street, though, the key is to see beyond the noise and recognize the inherent future potential a company presents. Ignore the price for the moment and concentrate on value, is an oft repeated mantra. Is the company on its way to solving previously solution-free problems? Is it cash strapped or financially secure? Does it have further catalysts down the line? All of these are issues that need to be considered when investing in a stock, and certainly in the volatile world of biotechs.Using TipRanks’ Stock Screener, we were able to zero in on 3 promising tickers in the biotech sector which the analysts think are ready to gain value in 2020. All three present serious upside potential, and what’s more, all currently boast a “Strong Buy” consensus rating from the Street. Let’s read the data.Immunomedics (IMMU)If you’re going to take your time to get something right, then you might as well really take your time. After almost 40 years of failed attempts and languishing in a perpetual development stage, Immunomedics might finally be on its way to getting a treatment to market.This biotech develops monoclonal antibody-based products for the treatment of cancer. The aforementioned almost-ready-to-launch drug is sacituzumab govitecan, a treatment for metastatic triple-negative breast cancer (TNBC), which combines a cancer-targeting antibody with an antitumor drug. The treatment is to be used as a “final attempt” drug following the failure of two previous therapies.Immunomedics was handed the dreaded CRL (complete response letter) from the FDA following its application last year after concerns not specifically related to the drug, but to “chemistry, manufacturing, and control” issues at the company’s manufacturing plant were raised. The concerns were addressed by IMMU and an application was resubmitted last month.Hopes are high as results from the drug’s clinical trials were better than those exhibited for chemotherapy treatments in second-line settings; Sacituzumab exhibited a 33% success rate in the third-line setting and progression free survival was 5.5 months. Chemo regime rates are in the mid-teens in both cases. The drug is also being studied as a potential early line treatment, too, and if it gets approval this year, expect Immunomedics’ share price to soar in 2020.H.C. Wainwright’s Ram Selvaraju is bullish on the cancer fighter. The 5-star analyst said, "We continue to believe that sacituzumab should potentially reach the market in early 3Q20 given the following: (1) the FDA previously reviewed sacituzumab's efficacy and safety profile and Immunomedics had a product label in hand, while the approval was solely subject to chemistry, manufacturing, and controls (CMC) review; (2) the issue cited in the Complete Response Letter (CRL) received in January 2019 was specifically CMC-related; (3) sacituzumab's clinically meaningful incremental efficacy benefit in third-line mTNBC relative to well-established historical controls; and (4) Immunomedics has had extensive dialog with FDA reviewers prior to the previous BLA submission, during the review and after the CRL."Selvaraju, therefore, maintained his Buy rating on IMMU. The analyst’s confidence is reflected by a raise of his price target: from $26 to $31, as it happens. The new target implies potential upside of 63%. (To watch Selvaraju’s track record, click here)The Street appears equally confident in IMMU’s future potential; 4 Buy ratings add up to a Strong Buy consensus rating. With an average price target of $28, the analysts believe Immunomedics can add 47% to its share price over the coming year. (See Immunomedics stock analysis on TipRanks) Revance Therapeutics (RVNC)After a disappointing 2019, which saw Revance’s share price drop by more than 18%, the neuromodulator-focused biotech has started 2020 with a bang; Revance stock is up by 38% year-to-date.So, what’s all the fuss about, then? The biotech recently secured a licensing deal with Swiss company, Teoxane Laboratories, for the exclusive US rights to its platform of hyaluronic-acid dermal fillers. These include the FDA-approved RHA 2, RHA 3, and RHA 4. Revance will issue 2.5 million shares to Teoxane in exchange for the rights. Additionally, the company also received the rights to RHA 1, a fourth filler currently in clinical trials, with data expected in 2021.There’s more to come in 2020, too. Revance recently filed a Biologics License Application (BLA) for DAXI, a long-lasting formulation of a neurotoxin treatment of moderate to severe glabellar (frown) lines. Revance expects an FDA approval for the treatment in 2H20, following which DAXI could potentially provide serious competition to a market dominated by Allergan's Botox.Needham’s Serge Belanger believes RVNC’s product line has the potential to take a big chunk out of the $5 billion neuromodulator market. The 4-star analyst said, “We view RVNC's DaxibotulinumtoxinA (Daxi), which has consistently demonstrated higher efficacy and longer duration than any of the current neuromodulators, as the first major neurotoxin innovation in the last 30 years. The recent BLA filing of Daxi in late November kicked off what should be a transformational period for RVNC in 2020 that include a potential Mylan opt-in for a biosimilar collaboration, numerous data readouts, most notably the pivotal Phase 3 cervical dystonia (CD) trial readout that will establish the product's therapeutic potential, and a likely first FDA approval and launch in 2H20.”Where does this leave Belanger, then? In the Buy section, naturally. Along with the reiteration, Belanger kept his price target at $32. This implies potential gains of 42% over the next 12 months. (To watch Belanger’s track record, click here)The frown warrior gets no frowns from the Street, either. 8 Buys spell out a unanimous Strong Buy consensus rating for Revance. With an average price target of $32.88, the upside potential comes in at 46%. (See Revance stock analysis on TipRanks) Theravance Biopharma (TBPH)Theravance Biopharma has a diversified portfolio focusing on therapies in a number of areas; these include respiratory, gastrointestinal, cardiovascular, infectious, inflammatory, and immunology diseases. Although the company has hit its targets over the last couple of years, the stock’s performance has not followed accordingly. Is this about to change in 2020?Theravance already has an FDA approved drug on the market. Yupelri, a treatment for chronic obstructive pulmonary disease (COPD) that came as the result of a partnership with Mylan, gained approval from the FDA at the end of 2018. According to Theravance, throughout the first three quarters of 2019, roughly 21,000 patients received the drug.The company also has additional revenue streams. GlaxoSmithKline provides a royalty of between 5.5% to 8.5% for global net sales of Trelegy Ellipta. The COPD treatment is approved in 38 countries and has snapped up a 31% market share since September 2017. Theravance also sold its drug for life-threatening bacterial infections, Vibativ, to Cumberland Pharmaceuticals. The deal included a $20 million upfront payment plus royalties of up to 20% of U.S. net sales (capped at $100 million).With further drug candidates in the pipeline, Cantor Fitzgerald’s Louise Chen believes Theravance is “undervalued and underappreciated.” Highlighting the commercial launches of Trelegy Ellipta and Yupelri, its success in executing its business objectives in 2019, and the company’s “best-in-class” pipeline, the analyst thinks TBPH has “strong momentum” heading into 2020.Accordingly, then, Chen reiterated an Overweight rating on TBPH and kept her price target of $55 as is. Should the target be met, investors will be taking home a very healthy 118% increase over the coming months. (To watch Chen’s track record, click here)Currently, Theravance has a Strong Buy consensus rating from the Street. The breakdown presents 5 Buys and 1 Hold rating. At $36.67, the average price target presents possible upside of 45%. (See Theravance stock analysis on TipRanks)
One subscriber asked about what I thought of Immunomedics . The company is a clinical-stage biopharmaceutical company that is "developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases". In this daily bar chart of IMMU, below, we can see three tests of the $12 area over the past year.
Immunomedics, a New Jersey biotech firm, says the Food and Drug Administration will begin reviewing its application to market an antibody treatment for breast cancer.
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 26.) Aimmune Therapeutics Inc (NASDAQ: AIMT ...
Baker Bros. Advisors paid $87.5 million for more Kodiak stock, while Avoro Capital paid $35 million for additional Immunomedics shares.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...
Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a positive ...
When it comes to stocks that can shoot up overnight, biotechs are the name of the game. This group’s extreme volatility lies in the fact that a single piece of good news like promising study results can cause share prices to climb to new heights, while the reverse also holds true.As a result, it’s often difficult to determine if names in this industry represent compelling investments. That being said, there are tools available that can help gauge which biotech stocks are poised for substantial long-term growth.Using TipRanks’ Best Stocks to Buy tool, we were able to zero in on 3 biotech stocks that have achieved a “Perfect 10” Smart Score. The metric weighs a variety of factors and combines them into a single numerical score, with 10 being the highest. Not to mention each has earned a ‘Strong Buy’ consensus rating, according to all of the ratings published by analysts in the last three months. Alexion Pharmaceuticals (ALXN)Alexion wants to improve the lives of patients suffering from rare diseases such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP) and other conditions. While best known for its Soliris therapy to treat aHUS, a disease that causes abnormal blood clots to form in small blood vessels in the kidneys, the company has recently expanded its pipeline and has several candidates in development.In its most recent quarter, ALXN highlighted its deals with Eidos, Stealth and Achillion as part of its efforts to diversify its offerings. It also expects to add four new clinical stage assets, including two in Phase 3 development. Bearing this in mind, management raised its total revenue guidance to between $4.86 billion to $4.89 billion. If achieved, this would demonstrate an 18% year-over-year gain at the midpoint of the range.With all of these promising developments, it’s no wonder that nine analysts have published bullish calls in just the last ten days. One of the analysts singing ALXN’s praises is Citigroup’s Mohit Bansal. He argues that the biotech is a growth stock trading like a value stock. He adds that the “strong” revenue guidance and recently expanded pipeline may be of interest to incremental investors. As a result, Bansal reiterated his Buy rating. (To watch Bansal’s track record, click here)The rest of the Street appears to echo the analyst’s sentiment. In just the last three months, ALXN has received 16 Buy ratings and 2 Holds, giving it a ‘Strong Buy’ analyst consensus. Its $155 average price target suggests 48% upside potential. (See Alexion stock analysis on TipRanks) Immunomedics (IMMU)Immunomedics uses antibody-based therapies to develop treatments for cancer, autoimmune and other diseases. With the company recently launching studies back in April and May, buzz surrounding this biotech has been building.The company recently announced the launch of its registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer. The study of its IMMU-132 drug will feature patients that have experienced failure of at least two but no more than four prior chemotherapy regimens for metastatic disease. IMMU also launched a Phase 2 open label study of its sacituzumab govitecan therapy to treat advanced solid tumors.On top of these trials, the biotech is recruiting for a Phase 2 trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. While investors will have to wait for the results from the trials, Piper Jaffray analyst Joseph Catanzaro sees significant upside in store for IMMU.“We believe Immunomedics is very well-positioned within triple-negative breast cancer and urothelial bladder cancer,” he commented. Based on all of the above factors, the analyst reiterated his Buy rating and $20 price target. This price target conveys his confidence in IMMU’s ability to surge 23% over the next twelve months. (To watch Catanzaro’s track record, click here)With only Buy ratings assigned in the last three months, the word on the Street is clear: IMMU is a ‘Strong Buy’. Additionally, it boasts 58% upside potential thanks to its $26 average price target. (See Immunomedics stock analysis on TipRanks) Coherus Biosciences (CHRS)By developing biosimilar treatments, Coherus hopes to give patients access to more affordable drugs. A biosimilar drug is a medicine or therapy that is very similar to an already approved biological medicine. While it may seem counterintuitive to develop a drug that resembles something already on the market, they are beneficial in that they provide more treatment options and potentially reduce costs.Following the January 3 launch of its UDENYCA drug to decrease the occurrence of infection in patients receiving anti-cancer drugs, the company has been performing solidly. CHRS saw its UDENYCA net sales reach about $120 million in the first half of 2019. Management stated that this figure was bolstered by strong exit unit market share of 13% at the end of June.All of this led to a 125% increase in net product revenue from the first quarter to the second. With the company developing a therapy similar to Amgen’s Enbrel drug to treat rheumatoid arthritis, some analysts tell investors CHRS is primed for strong long-term growth.Barclays’ Balaji Prasad is one of the analysts maintaining a bullish thesis. While stating that shares experienced some weakness following AMGN’s favorable Enbrel patent ruling against Novartis, he remains very optimistic. He views any share weakness as an opportunity to add a "fundamentally sound company”. This played into his decision to reiterate his Buy rating and $31 price target. (To watch Prasad’s track record, click here)Similarly, other analysts take a bullish approach when it comes to CHRS. It earns a ‘Strong Buy’ Street consensus based on the 6 Buy ratings assigned over the last three months. The biotech stock’s potential twelve-month gain also comes in at 91% according to its $32 average price target. (See Coherus stock analysis on TipRanks)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. Sacituzumab is in the most advanced stage of clinical development for treating patients with metastatic triple negative breast cancer, or mTNBC. On July 18, 2018, the FDA accepted the BLA for the regulatory review of sacituzumab govitecan as a treatment option for mTNBC in the third-line setting and above, fixing the PDUFA action date at Jan. 18, 2019.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. An Immunomedics, Inc. (NASDAQ: IMMU) director and an executive each stepped up to the buy window this past week. The company released positive trial data at the European Society for Medical Oncology (ESMO) Annual Congress.
Whilst it may not be a huge deal, we thought it was good to see that Bryan Ball, who is a company insider, recently...